Professor Seeberger is regarded as one of the world’s leading experts in carbohydrate chemistry and biology, and is the global authority on automated carbohydrate synthesis technology. Prof. Seeberger received his Vordiplom in 1989 from the Universität Erlangen-Nürnberg, where he studied chemistry as a Bavarian government fellow. In 1990 he moved as a Fulbright scholar to the University of Colorado where he earned his Ph.D. in biochemistry under the guidance of Marvin H. Caruthers in 1995. After a postdoctoral fellowship with Samuel J. Danishefsky at the Sloan-Kettering Institute for Cancer Research in New York City he became Assistant Professor at the Massachusetts Institute of Technology in January 1998 and was promoted to Firmenich Associate Professor of Chemistry with tenure in 2002. In June 2003 he assumed a position as Professor for Organic Chemistry at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland and a position as Affiliate Professor at the Burnham Institute in La Jolla, CA.
In 2009 Prof. Seeberger will become Director at the Max-Planck Institute for Colloids and Surfaces in Potsdam and Professor at the Free University of Berlin. Professor Seeberger’s research has been documented in over 180 articles in peer-reviewed journals, two books, fifteen issued patents and patent applications, more than 100 published abstracts and more than 370 invited lectures. Among other awards he received the Arthur C. Cope Young Scholar and Horace B. Isbell Awards from the American Chemical Society (2003) and the Otto-Klung Weberbank Prize for Chemistry (2004). In 2007 he received the Havinga Medal, the Yoshimasa Hirata Gold Medal and the Körber Prize for European Sciences. In 2007 and 2008 he was selected among “The 100 Most Important Swiss” by the magazine “Schweizer Illustrierte.” In (month) of 2008, he will receive the UCB-Ehrlich Award for Excellence in Medicinal Chemistry.
Professor Seeberger is the Editor of the Journal of Carbohydrate Chemistry and serves on the editorial advisory boards of eleven other journals. He is a founding member of the board of the Tesfa-Ilg “Hope for Africa” Foundation that aims at improving health care in Ethiopia in particular by providing access to malaria vaccines and HIV treatments. He is a co-founder of Ancora Pharmaceuticals Inc. and serves as a consultant and or on the scientific advisory board of several companies. In 2006 he served as president of the Swiss Academy of Natural Sciences.
Dr. Roberts has extensive experience as entrepreneur, executive and active board member within the biotechnology and materials science fields. Currently, Dr. Roberts serves as a General Partner at North Bridge Venture Partners where he finances and builds companies that develop products using chemistry, materials science and/or materials engineering. Prior to joining North Bridge, Dr. Roberts was involved in co-founding several companies including Arsenal Medical, Surface Logix, Nano-Terra, and Ancora. Before his career as an entrepreneur, Dr. Roberts worked in business development at GelTex Pharmaceuticals (acquired by Genzyme) and was responsible for new product and business development at Sentry Products, a life science venture wholly owned by Union Carbide Corporation (acquired by Dow Chemical).
Recently, along with Harvard University, Dr. Roberts co-founded Diagnostics For All, Inc., a non-profit organization that is developing a materials platform to make low cost diagnostics for poor and rural populations in developing nations. He currently serves as chairman of Diagnostics For All, vice-chairman for nano-terra, and on the advisory boards for MIT’s Deshpande Center for Innovation, Harvard’s Nanoscale Science and Engineering Center, and Duke’s School of Biomedical Engineering. In 1999, he was named by MIT’s Technology Review as one of the world’s top 100 young entrepreneurs. Dr. Roberts received his B.S. and Ph.D. in organic chemistry from Duke University and was a national Science Foundation Fellow at Harvard University’s Department of Chemistry and Chemical Biology. He also earned his M.B.A. from the MIT Sloan School of Management.
Mr. White is a senior investment management professional with extensive experience with early and late stage companies at the board level having served on several private equity advisory boards representing over $4 billion in global assets. Mr. White received his B.S. in Pharmacy at Florida A&M University in 1988. After working for Eli Lilly and Company for four years, Mr. White entered the University of Chicago’s Graduate School of Business. In 1995 he received his M.B.A. in Analytic Finance and Statistics. Mr. White has held various global asset allocation and foreign exchange positions in his investment management career and has worked for Goldman Sachs Asset Management, Putnam, Scudder Kemper and also founded Gracián Capital Management. From 2002 to 2006, he served as the Executive Director of the $1.8 billion Massachusetts Bay Transportation Authority Retirement Fund. Currently, Mr. White is the Chief Investment Officer for Fletcher Asset Management. Mr. White also currently serves on the Board of Trustees for Florida A&M University, the Board of Governors for Tufts Medical Center and the Advisory Board for African Presidential Archives and Research Center at Boston University. Previously, he also served as Vice-Chair of the University of Massachusetts Board of Trustees where he chaired a number of committees including Commercial Ventures and Intellectual Property.
Mr. Jamison is the President, Chief Operating Officer and Managing Director of the Harris and Harris Group. From 2002 to 2004, Mr. Jamison served as Vice President of Harris & Harris Group. Mr. Jamison also served as Chief Financial Officer from 2005 to 2007. Prior to joining the Company, Mr. Jamison worked for five years as a Senior Technology Manager at the University of Utah Technology Transfer Office, where he managed intellectual property for the University of Utah. This included assessing technologies in both the biological sciences and the physical sciences, working with patent attorneys to develop patent protection, and developing and marketing these technologies with industry. He is a Co-Editor-in-Chief, Journal of Nanotechnology Law & Business and Co-Chair of the Advisory Board, Converging Technology Bar Association. He was graduated from Dartmouth College (B.A.) and the University of Utah (M.S.).
Copyright © 2008-2012 Ancora Pharmaceuticals Inc. All rights reserved.
200 Boston Avenue, Suite 4975, Medford, MA 02155
Web site design and development by Sky Dog Technologies.